Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Organogenesis Holdings's enterprise value is €349.9 Mil.
Organogenesis Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-2.4 Mil. Therefore, Organogenesis Holdings's EV-to-EBITDA for today is -147.47.
The historical rank and industry rank for Organogenesis Holdings's EV-to-EBITDA or its related term are showing as below:
FRA:2PQ'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -402.79 Med: 7.83 Max: 640.15
Current: -326.89
During the past 11 years, the highest EV-to-EBITDA of Organogenesis Holdings was 640.15. The lowest was -402.79. And the median was 7.83.
FRA:2PQ's EV-to-EBITDA is ranked worse than 100% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.33
vs FRA:2PQ: -326.89
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Organogenesis Holdings's PE Ratio (TTM) for today is calculated as:
Organogenesis Holdings's share price for today is €1.62.
Organogenesis Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.750.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2PQ vs AKBA, TKNO, EBS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organogenesis Holdings EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Organogenesis Holdings's EV-to-EBITDA falls into.
Organogenesis Holdings's current Enterprise Value is €349.9 Mil.
Organogenesis Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organogenesis Holdings (FRA:2PQ) has a EV-to-EBITDA of -147.47 as of Aug. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Organogenesis Holdings. According to the industry distribution chart, Organogenesis Holdings ranks #999999 out of 734 companies in the Drug Manufacturers industry.
Is Organogenesis Holdings' EV-to-EBITDA too high?
Organogenesis Holdings' current EV-to-EBITDA is -147.47. Based on the distribution chart, Organogenesis Holdings ranks #999999 out of 734 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Organogenesis Holdings has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' EV-to-EBITDA compare to AKBA and TKNO?
According to the Drug Manufacturers industry distribution chart, Organogenesis Holdings ranks #999999 out of 734 companies for EV-to-EBITDA. This places Organogenesis Holdings in the lower half of its industry. The industry median EV-to-EBITDA is 13.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.33, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Organogenesis Holdings. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organogenesis Holdings's current EV-to-EBITDA is -147.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (FRA:2PQ) is currently considered Possible Value Trap. The stock's GF Value™ is €2.60, compared to a current price of €1.62 — trading 37.7% below its estimated fair value. The current EV-to-EBITDA is -147.47. Organogenesis Holdings' overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Organogenesis Holdings (FRA:2PQ), the current EV-to-EBITDA is -147.47 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organogenesis Holdings (FRA:2PQ) Overvalued in 2026?
Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued.
The current stock price of €1.62 is trading 37.7% below its estimated GF Value™ of €2.60.
GuruFocus considers Organogenesis Holdings to be Possible Value Trap.
Key valuation signals for FRA:2PQ:
EV-to-EBITDA: -147.47
GF Value™: €2.60 vs. price of €1.62 (37.7% below fair value)
No single metric tells the full story. See the FRA:2PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
66GF Score
Get the complete analysis for FRA:2PQ
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2PQ has been successfully added to your 
